Rogé Report

Bio-Reference Labs: Sustainable Long-Term Growth

By: Steven M. Roge, CMFC Bio-Reference Laboratories (BRLI) Share Price: $19 Intrinsic Value: $27 Buy Below: $21 Business description and background: Bio-Reference Laboratories Inc. is the fourth largest full service laboratory in the United States and the largest independent regional laboratory in the Northeastern market, primarily a clinical testing laboratory servicing physician offices with concentrations...
Read More

S&P’s Downgrade of Long Term U.S. Debt

The Standard and Poor’s (S&P) downgrade of long-term U.S. debt from AAA to AA+ is sad, but it is not news.  Everyone already knew we were in trouble and to act surprised is unjustified. Now we and our politicians can no longer deny it.  It’s official, which may be good for us long-term.  While the...
Read More

A Goal in Search of Leadership

Our elected leaders in Washington, D.C. are playing a dangerous game of chicken. They are making everyone nervous about the deadline (August 2, 2011) for extending the debt ceiling. While every expert on the subject, including Congress, knows that the only solution is to raise the debt ceiling, they are using this to score points...
Read More

Who Are the Top 50 Women in Wealth for 2011?

You might be surprised to learn that one of the top 50 women in the field of wealth management is none other than my wife Rosanne Rogé.  I am not surprised, but very proud that she has been chosen to be on Advisor One’s list of the top 50 Women in Wealth for 2011. Advisor...
Read More

The Future of the Euro

By: Steven M. Roge, CMFC The future of the euro has consumed global investors over the past two years. While global markets have intensely focused on the potential insolvency of Economic Monetary Union (EMU) members, the current political and economic turmoil in Europe strikes at the very heart of the “European Union (EU) project.” Indeed,...
Read More

Hi-Tech Pharmacal: Bright Future in Generic Drugs

By: Steven M. Roge, CMFC Hi-Tech Pharmacal Co. (HITK) (share price $26.52; intrinsic value $38.83; we recommend buying below $27.18) develops, manufactures, markets, and sells generic, prescription, over-the-counter (OTC), and nutritional products in liquid and semisolid dosage forms in the United States. It produces a range of products for various disease states, including asthma, bronchial...
Read More

World Equity Valuations by the Shiller PE Ratio

By: Steven M. Roge, CMFC Stock market and investing has been gripping many young adults these days and the first thing that anybody entering investing learns of, is the price to earnings ratio or PE ratio. It is a preliminary criteria but it is not sufficient to take investment decisions on a standalone basis. However,...
Read More

A Long-Term Care Primer: The Need and the LTCI Option

Rosanne Roge, CFP, RFG, CSA The baby boomer generation – defined by the Census Bureau as those born between 1946 and 1964 – is going to have a major impact on many aspects of the economy, but the most important will be health care. The oldest boomers are turning 65 this year. This cohort will...
Read More

Why an Emerging Market Bubble May Be on the Horizon

By: Steven M. Roge, CMFC In recent years, emerging markets have attracted significant attention and capital, neither of which was undeserved. First, they gained attention because they provided unique investment opportunities in developing countries with tremendous growth potential, unlike “stodgy” options such as the United States and the United Kingdom. Second, with the advent and...
Read More
1 20 21 22 23 24 26

Like Us on Facebook